KR101699572B1 - 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물 - Google Patents

주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물 Download PDF

Info

Publication number
KR101699572B1
KR101699572B1 KR1020127002287A KR20127002287A KR101699572B1 KR 101699572 B1 KR101699572 B1 KR 101699572B1 KR 1020127002287 A KR1020127002287 A KR 1020127002287A KR 20127002287 A KR20127002287 A KR 20127002287A KR 101699572 B1 KR101699572 B1 KR 101699572B1
Authority
KR
South Korea
Prior art keywords
berberine
treatment
injections
topical
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127002287A
Other languages
English (en)
Korean (ko)
Other versions
KR20120047240A (ko
Inventor
슈엔-루 훙
웬-흥 청
츠웬 장
Original Assignee
더만 바이오메디슨 코. 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더만 바이오메디슨 코. 엘티디. filed Critical 더만 바이오메디슨 코. 엘티디.
Publication of KR20120047240A publication Critical patent/KR20120047240A/ko
Application granted granted Critical
Publication of KR101699572B1 publication Critical patent/KR101699572B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020127002287A 2009-06-30 2010-06-30 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물 Expired - Fee Related KR101699572B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22172509P 2009-06-30 2009-06-30
US61/221,725 2009-06-30
PCT/CN2010/000983 WO2011000218A1 (en) 2009-06-30 2010-06-30 Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177001412A Division KR20170010442A (ko) 2009-06-30 2010-06-30 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물

Publications (2)

Publication Number Publication Date
KR20120047240A KR20120047240A (ko) 2012-05-11
KR101699572B1 true KR101699572B1 (ko) 2017-01-24

Family

ID=43410481

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020127002287A Expired - Fee Related KR101699572B1 (ko) 2009-06-30 2010-06-30 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물
KR1020177027790A Ceased KR20170116231A (ko) 2009-06-30 2010-06-30 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물
KR1020177001412A Ceased KR20170010442A (ko) 2009-06-30 2010-06-30 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177027790A Ceased KR20170116231A (ko) 2009-06-30 2010-06-30 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물
KR1020177001412A Ceased KR20170010442A (ko) 2009-06-30 2010-06-30 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물

Country Status (16)

Country Link
US (1) US9486402B2 (enExample)
EP (1) EP2448577B1 (enExample)
JP (2) JP6159084B2 (enExample)
KR (3) KR101699572B1 (enExample)
CN (2) CN105534978A (enExample)
AU (1) AU2010268647B2 (enExample)
BR (1) BRPI1012128A2 (enExample)
CA (1) CA2766834C (enExample)
ES (1) ES2600909T3 (enExample)
HK (1) HK1224206A1 (enExample)
IL (1) IL217264A (enExample)
MX (1) MX344787B (enExample)
NZ (1) NZ597645A (enExample)
PL (1) PL2448577T3 (enExample)
RU (2) RU2533458C2 (enExample)
WO (1) WO2011000218A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201538156A (zh) 2013-12-19 2015-10-16 Twi Biotechnology Inc 小蘗鹼配方及其用途
US20160263092A1 (en) * 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
HK1249068A1 (zh) * 2015-06-24 2018-10-26 安成生物科技股份有限公司 小檗碱制剂的治疗用途
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
MX2018012719A (es) 2016-04-19 2019-05-30 Us Health Ram negativas para tratar la dermatitis atopica.
US10675260B2 (en) 2017-01-19 2020-06-09 Twi Biotechnology, Inc. Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders
EP3398448A1 (en) 2017-05-05 2018-11-07 Vall Garraf, S.L. Fattening additive for animal nutritional composition
WO2019114705A1 (zh) 2017-12-13 2019-06-20 上海小午医药科技有限公司 一种用于预防或治疗与egfr被抑制相关疾病的方法
CN111989095A (zh) 2018-04-16 2020-11-24 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
BR112020021274A2 (pt) * 2018-04-18 2021-04-13 Forte Subsidiary, Inc. Composições para o tratamento de doenças da pele
CN108329310A (zh) * 2018-05-07 2018-07-27 深圳市迪克曼科技开发有限公司 黄藤素的制备方法
CA3099903A1 (en) 2018-05-11 2019-11-14 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions
CN110882246B (zh) * 2018-09-08 2022-12-23 西南大学 不同生物活性的黄连生物碱的提取方法及应用
JP2020045338A (ja) * 2018-09-12 2020-03-26 大正製薬株式会社 外用組成物
US11802103B2 (en) 2018-09-25 2023-10-31 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
JP6535146B1 (ja) * 2019-03-08 2019-06-26 佐藤製薬株式会社 皮膚バリア機能改善剤
RU2697854C1 (ru) * 2019-05-14 2019-08-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ комбинированной наружной терапии эритематозно-папулезной розацеа
CN113440613A (zh) * 2020-03-26 2021-09-28 轶诺(浙江)药业有限公司 小檗碱类似物与jak抑制剂在胃肠道炎症性疾病治疗中的用途
CN116370469A (zh) * 2023-04-27 2023-07-04 常州大学 四氢小檗碱类化合物对trpv3的抑制应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286054A1 (en) * 2005-06-15 2006-12-21 Apollo Pharmaceutical, Inc. Pharmaceutical compositions for the treatment of psoriasis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150920A (ja) * 1984-08-20 1986-03-13 Ichimaru Fuarukosu Kk 黄柏抽出エキス含有液の製造法
JPS63179812A (ja) * 1987-01-22 1988-07-23 Shiseido Co Ltd 皮膚外用剤
JP2609564B2 (ja) * 1991-05-31 1997-05-14 政夫 斎藤 アレルギー性皮膚炎用クリーム及びその製造方法
CN1085600A (zh) * 1993-07-07 1994-04-20 南宁市迪生新技术研究所 防治性病、传染病的杀菌保健香皂和浴液
CN1182788A (zh) * 1997-02-03 1998-05-27 熊光明 一种防治性病传染病的保健洗涤用品
US6482839B1 (en) * 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
JP2001335485A (ja) * 2000-05-31 2001-12-04 Pola Chem Ind Inc メラノサイトのデンドライトの伸長抑制剤及びそれを含有する化粧料
KR20030082200A (ko) * 2002-04-17 2003-10-22 주식회사 엘지생활건강 베르베린을 함유하는 아토피성 피부염 예방 및 완화용조성물
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
WO2004093876A2 (en) * 2003-04-03 2004-11-04 The Board Of Trustees Of The University Of Illinois Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders
US7205006B2 (en) * 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
KR101045658B1 (ko) 2003-11-17 2011-07-01 쎄데르마 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물
US20050158404A1 (en) 2003-11-18 2005-07-21 Goodless Dean R. Composition and method for treatment of acne
EP1591125A1 (de) * 2004-04-19 2005-11-02 Universitätsklinikum Freiburg Pharmazeutische Zusammensetzung enthaltend Extrakte aus Flechten und Johanniskraut
CN100441183C (zh) * 2005-08-29 2008-12-10 中国医学科学院皮肤病研究所 盐酸13-己基小檗碱和盐酸13-己基巴马汀制备治疗湿疹、皮炎和银屑病的药物用途
DE202010004750U1 (de) 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286054A1 (en) * 2005-06-15 2006-12-21 Apollo Pharmaceutical, Inc. Pharmaceutical compositions for the treatment of psoriasis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Phytochemical, 15, 340-347쪽(2008.)*

Also Published As

Publication number Publication date
EP2448577A1 (en) 2012-05-09
EP2448577A4 (en) 2012-12-26
KR20170010442A (ko) 2017-01-31
ES2600909T3 (es) 2017-02-13
BRPI1012128A2 (pt) 2016-03-29
RU2533458C2 (ru) 2014-11-20
CN102481290A (zh) 2012-05-30
HK1224206A1 (zh) 2017-08-18
WO2011000218A1 (en) 2011-01-06
RU2014136492A (ru) 2016-03-27
KR20120047240A (ko) 2012-05-11
US20120165357A1 (en) 2012-06-28
PL2448577T3 (pl) 2017-02-28
US9486402B2 (en) 2016-11-08
CA2766834A1 (en) 2011-01-06
AU2010268647A1 (en) 2012-02-09
JP2012531448A (ja) 2012-12-10
CA2766834C (en) 2017-04-25
IL217264A (en) 2017-01-31
KR20170116231A (ko) 2017-10-18
EP2448577B1 (en) 2016-09-14
AU2010268647B2 (en) 2015-01-15
JP6159084B2 (ja) 2017-07-05
NZ597645A (en) 2014-03-28
MX2011014006A (es) 2012-06-12
MX344787B (es) 2017-01-05
RU2671492C2 (ru) 2018-11-01
RU2012102898A (ru) 2013-08-10
IL217264A0 (en) 2012-02-29
JP2017082019A (ja) 2017-05-18
CN105534978A (zh) 2016-05-04

Similar Documents

Publication Publication Date Title
KR20170116231A (ko) 주사 또는 홍안 관련 피부 질환의 치료를 위한, 베르베린 또는 그의 유사체를 함유하는 조성물
US10786531B2 (en) Mineral salt-sulfonic acid compositions and methods of use
US11471501B2 (en) Pharmaceutical composition for use in the treatment of prostate pathologies
CN103458884A (zh) 用于治疗肾病的方法及组合物
US20210046166A1 (en) Systems for treating dermal inflammatory conditions
JP2021195305A (ja) 老化細胞の排除促進剤
CN104220083A (zh) 用于治疗动脉硬化性血管疾病的方法和组合物
JP2018529752A (ja) サンダルウッド油及び口腔粘膜炎に関連するその用途
KR102963500B1 (ko) 무화과 추출물을 포함하는 건선의 예방 및 치료용 조성물
US20170152285A1 (en) Extracting method of kuguacin, pharmaceutical composition comprising the kuguacin and use thereof
CN120478430B (zh) 一种治疗特应性皮炎的组合物及其应用
KR102751617B1 (ko) 이소클로로겐산 또는 이의 염을 유효성분으로 포함하는 피부 로사시아 예방 및 개선용 조성물
KR101574591B1 (ko) 신곡 추출물을 포함하는 상처 치료용 조성물
JP2024128926A (ja) 顔の皮膚状態の改善剤
JPH10306034A (ja) 皮膚治療剤
KR100785419B1 (ko) 항천식 활성을 가지는 시금치 추출물
KR20240032428A (ko) 무화과 추출물을 포함하는 건선의 예방 및 치료용 조성물
JP2019099541A (ja) 亜鉛トランスポーター発現促進剤
IL264076B (en) Treatment of follicular tonsillitis using plant extracts containing carnosic acid

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20200121

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220119

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220119